PRF1 and X-linked lymphoproliferative disease: These serious adverse events seem to have been overcome by the introduction of safer self-inactivating lentiviral vectors, and new studies are under way for a number of IEIs, including RAG-SCID, X-linked lymphoproliferative syndrome, and perforin deficiency197.